The precision genomic testing market size was valued at USD 2.74 billion in 2024 and is expected to reach USD 6.26 billion by 2032, growing at a CAGR of 10.89% over 2025-2032.
The global precision genomic testing market is witnessing rapid advancement due to the convergence of next-generation sequencing, AI-driven analytics, and personalized medicine. Increasing demand for tailored diagnostics in oncology, reproductive health, and rare diseases is a key growth factor. The U.S. precision genomic testing market is notably driven by payer coverage expansion and the integration of genomic data in clinical workflows. A significant surge in demand is observed, with nearly 8–12 times more requests for genome-based diagnostics over the past decade. Investments in this space are robust over USD 10 billion in venture capital funneled into genomic startups between 2020 and 2024.
For instance, in May 2024, Illumina launched its PrimateAI-3D tool for clinical interpretation of genetic variants, advancing predictive genomics.
Additionally, the R&D spending by key precision genomic testing companies such as Thermo Fisher, Illumina, and Guardant Health has increased steadily, supporting innovation in AI and liquid biopsy tools. Regulatory support is strengthening: the U.S. FDA’s approval of multi-gene NGS panels and the CMS’ reimbursement coverage expansion are propelling adoption. Furthermore, cloud-based genomic data platforms and AI-enabled interpretation tools are improving accessibility and scalability, which is accelerating precision genomic testing market growth and transforming the healthcare landscape.
In July 2024, Guardant Health secured FDA approval for its Shield blood-based colorectal cancer screening test, reinforcing the regulatory momentum in the U.S. precision genomic testing market.
Market Dynamics:
Drivers:
Technological Advancements, Rising Investments, and Increasing Clinical Utility are the Major Factors Fueling the Growth of the Precision Genomic Testing Market
The precision genomic testing market is primarily driven by increasing clinical adoption of genomic profiling across oncology, cardiology, and infectious diseases. Demand is surging due to the rise in personalized medicine and preventive health programs, with more than 80% of oncologists in the U.S. using some form of genetic testing to guide treatment decisions. On the supply side, massive R&D investments by companies like Exact Sciences and Agilent Technologies, which spent over USD 200 million collectively in R&D in 2023, are fueling innovation in multiplex assays, cfDNA tests, and CRISPR-based diagnostics.
Furthermore, regulatory support is accelerating adoption; the FDA approved FoundationOne CDx and MSK-IMPACT as companion diagnostics, setting clinical precedence. The global rise in genomic data generation, estimated at 40 exabytes annually, is also pushing demand for precision testing platforms integrated with AI and cloud computing. Additionally, initiatives such as the Global Alliance for Genomics and Health (GA4GH) are setting frameworks for data interoperability and privacy, further enabling growth in the global precision genomic testing market. These drivers combined are accelerating both clinical demand and commercial innovation, supporting sustainable precision genomic testing market growth.
Restraints:
High Costs, Data Privacy Concerns, and Disparities in Access are the Key Limitations Hindering the Growth of the Global Precision Genomic Testing Market
Despite significant progress, the precision genomic testing market faces several barriers. A major restraint is the high cost of sequencing and test interpretation, which limits accessibility in low-resource healthcare systems.
For instance, while whole-genome sequencing costs have dropped, downstream analysis and clinical interpretation remain expensive, averaging USD 1,000–USD 2,000 per patient.
Additionally, data security and patient privacy are growing concerns; a recent survey by the American Medical Association found that 58% of clinicians worry about the misuse of genomic data in insurance and employment settings. Moreover, regulatory inconsistencies across regions, especially in the validation and reimbursement of LDTs (Laboratory Developed Tests), slow down market penetration. The shortage of skilled genetic counselors also adds to operational challenges, with only 1 genetic counselor available for every 100,000 patients in many regions. Furthermore, lack of standardized clinical guidelines in emerging markets and limited awareness among general practitioners affect test uptake. These challenges collectively inhibit broader clinical adoption, particularly in non-oncology settings, despite the potential of precision testing. Addressing these restraints is critical for realizing the full potential of the precision genomic testing market share globally.
Segmentation Analysis:
By Product & Service
Consumables were the largest product segment in 2024, representing more than 35% of the precision genomic testing market share. Owing to their continual use in each cycle of genomic testing (e.g., extraction kits, library preparation reagents, amplification buffers), demand is expected to be stable. The bulk of consumables are consumed in labs and testing companies, not only as high-throughput platforms, for instance, NGS, become more prevalent.
By contrast, the software segment has been growing fastest, reflecting the rise of AI-based genomic interpretation tools. The requirement to process big amounts of genomic data and provide clinically relevant findings is also driving the investment in data analytics platforms. Cloud-based applications and incorporated workflow mapping software are becoming increasingly popular, with diagnostic labs and predictive diagnostic biotech firms leading the charge.
By Technology
The next-generation sequencing (NGS) segment accounted for the largest share of the global precision genomic testing market in 2024, and was valued at over 45%. Its high throughput, decreasing cost, and the possibility to interrogate multiple genes at the same time have become the basis of a wide array of applications including cancer genomics, inherited disease diagnostics, and population-scale screening. Adoption of NGS is skyrocketing as the technology transitions out of research labs and into the clinic.
The CRISPR/Cas system was identified as the most rapidly expanding technology segment, driven by increasing utilization in diagnostics and target validation. Its capacity to locate specific DNA mutations with high precision is transforming areas such as rare disease diagnosis and pathogen detection. This proliferation of CRISPR-based diagnostic startups and patent applications also illustrates its increasing impact in precision diagnostics.
By Application
In 2024, oncology held the application industry share of 57% of the precision genomics testing market. Statement on: Cancer remains a major global health issue, and precision testing is utilized to inform treatment choice, to monitor disease recurrence, and response to drugs. Meanwhile, companion diagnostics and liquid biopsies have added new life to this side of the segment.
In contrast, reproductive & prenatal health is the fastest-growing application sector. Rising consciousness regarding early genetic diagnosis, along with growing maternal age and demand for non-invasive prenatal screening (NIPS), is promoting the market development. It’s also becoming more common for fertility/IVF clinics to offer carrier screening and preimplantation genetic diagnosis (PGD), marking a move towards proactive, genomics-led reproductive care. It has both regulatory approval and technical availability to help this expansion process.
By Sample Type
Blood samples dominated the landscape on a sample type basis in 2024, with more than 44% of the market. Blood is still considered the gold standard for most genomic analyses because it is easy to collect, non-invasive, and can be used for technologies such as cfDNA analysis and liquid biopsy. Oncology, infectious disease, and rare disease applications are common use cases for blood-derived samples.
Meanwhile, saliva samples are the fastest-growing sample type, mainly driven by their adoption for direct-to-consumer (DTC) testing. Genomic assays testing on saliva are non-invasive, easy to use, and appropriate for remote, large-scale population research. Adoption is growing due to their expanded use in ancestry, wellness, and pharmacogenomics testing. Furthermore, the regulatory support for at-home collection approaches has improved their clinical and market potential.
By End User
The end-user segment is dominated by diagnostic laboratories in 2024, with market share of over 38%. These laboratories act as centralized high-throughput processing centers that have standardized and validated assays. Their utilization of advanced genomic platforms and expertise in NGS, PCR, and microarray techniques along with other sequencing technologies makes them the preferred supplier to hospitals, clinics, and laboratories.
On the other hand, pharmaceutical & biotechnology companies is the fastest-growing end-user segment. Growth is being enabled by companion diagnostics, pharmacogenomics, and genomic-based drug discovery. These firms are employing precision genomics testing to identify sub-populations of sick as well as well patients to validate new drug targets and to prevent drop outs in clinical trials. Investments in biomarker platforms and partnerships with diagnostic developers support their increasingly important role in this market.
Regional Analysis:
The precision genomic testing market in North America in 2024 was led by a well-developed healthcare system, growing use of genomics in clinical settings, and favorable reimbursement scenario.
The U.S. precision genomic testing market size was valued at USD 0.87 billion in 2024 and is expected to reach USD 1.93 billion by 2032, growing at a CAGR of 10.43% over 2025-2032. The U.S. is the largest country in this region, and it's responsible for more than 65% of whole North American market. That supremacy has recently been strengthened by a proliferation of precision medicine projects, including NIH’s “All of Us” and FDA greenlighting of multi-gene diagnostic panels. Significant R&D spend of over USD 50 billion a year in biomedical research and a strong representation from key players such as Illumina, Thermo Fisher, and Guardant Health also underpins the region. Canada is also broadening its footprint and is home to government-supported organizations, including Genome Canada, which, by investing over CAD 940 million in genomics projects, is supporting a growing North American market.
Europe represents the second leading position in the overall precision genomic testing market due to the favorable regulatory pathways, government funding, and growing application of genomics in healthcare. Germany is the largest country in the region, and the high adoption of tests and government-supported precision health programs is driving the market. The country has deployed national genome sequencing efforts and invested significantly in AI-powered diagnostics. The UK is also moving swiftly, as exemplified by initiatives such as Genomics England or the integration of genomic medicine into the NHS. France and Italy see continued uptake in Oncology and Prenatal screening. Supported by Europe’s focus on ethical use of genomic data and cross-border regulation for data sharing, a joined-up framework has been established that has driven development and uptake of tests.
The precision genomic testing market in Asia Pacific is growing at the fastest rate owing to increasing access to healthcare, growing awareness, and supportive government initiatives. China is leading the pack in the region, supported by a national genomics strategy and significant investments in biotech with over USD 12 billion pledged for genomic medicine R&D up to 2025. Domestic innovation is being led by companies such as BGI Genomics and WuXi NextCODE. India is also seeing rapid growth, underpinned by government programs such as Genomics for Public Health and growing demand for DTC tests. Japan is still ahead of the game in the integration of research, especially oncology, in a close connection between academia and industry. High population-scale sequencing, rising middle-class healthcare spend, and adoption of AI-tech are amongst the factors that make Asia Pacific the fastest-growing region.
Leading precision genomic testing companies driving the market include Thermo Fisher Scientific, Illumina, Roche, QIAGEN, Agilent Technologies, Guardant Health, Foundation Medicine, Exact Sciences, Myriad Genetics, GRAIL, Oxford Nanopore Technologies, PacBio, 10x Genomics, Genomic Health, Revvity, GenScript, Maravai LifeSciences, Abbott Laboratories, Danaher Corporation, NantHealth.
In June 2024, Illumina Inc. launched its NextSeq 1000Dx sequencing system, receiving FDA 510(k) clearance for clinical use. This development strengthens its diagnostic platform portfolio and supports broader clinical adoption of genomic testing in certified labs.
In April 2024, Roche announced the CE-IVD approval of its AVENIO Tumor Tissue CGP Kit, enabling comprehensive genomic profiling (CGP) in decentralized labs across Europe. This advancement aims to enhance precision oncology access beyond centralized testing facilities.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 2.74 billion |
| Market Size by 2032 | USD 6.26 billion |
| CAGR | CAGR of 10.89% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product & Service [Consumables (Kits, Reagents), Instruments, Software, Services, Others (Laboratory automation tools, Storage and logistics solutions specific to genomic workflows)] • By Technology [Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray Technology, Sanger Sequencing, CRISPR/Cas Systems, Others (Whole Genome Amplification (WGA), Nanopore sequencing, Digital PCR (dPCR))] • By Application [Oncology, Cardiovascular Diseases, Neurological Disorders, Reproductive & Prenatal Health, Infectious Diseases, Rare Diseases, Others (Autoimmune diseases, Metabolic disorders, Personalized wellness, etc.)] • By Sample Type [Blood Samples, Tissue Samples, Saliva Samples, Urine Samples, Others (Buccal swabs, Amniotic fluid, etc.)] • By End User [Hospitals and Clinics, Diagnostic Laboratories, Research & Academic Institutes, Pharmaceutical & Biotechnology Companies, Others (Contract research organizations (CROs), Direct-to-consumer (DTC) genetic testing companies)] |
| Regional Analysis/Coverage | North America (U.S., Canada), Europe (Germany, France, UK, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, Egypt, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America) |
| Company Profiles | Thermo Fisher Scientific, Illumina, Roche, QIAGEN, Agilent Technologies, Guardant Health, Foundation Medicine, Exact Sciences, Myriad Genetics, GRAIL, Oxford Nanopore Technologies, PacBio, 10x Genomics, Genomic Health, Revvity, GenScript, Maravai LifeSciences, Abbott Laboratories, Danaher Corporation, NantHealth. |
Ans: The precision genomic testing market refers to the segment of healthcare focused on using genomic information to tailor diagnosis, treatment, and prevention strategies. It involves advanced DNA sequencing technologies and bioinformatics to support precision healthcare.
Ans: Key drivers include increasing adoption of personalized medicine, rapid advancements in NGS technologies, and growing demand for genomic profiling in oncology and rare diseases.
Ans: North America, particularly the U.S., dominates due to strong regulatory support, R&D spending, and clinical integration, followed by Europe and the rapidly growing Asia Pacific market.
Ans: Major precision genomic testing companies include Illumina, Thermo Fisher Scientific, Roche, QIAGEN, Guardant Health, and 10x Genomics, all driving precision healthcare innovation.
Ans: NGS technologies are foundational in enabling fast, scalable, and cost-effective DNA sequencing, supporting applications from genomics in oncology to infectious disease diagnostics.
Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Product & Service
2.3.2 Market Size By Technology
2.3.3 Market Size By Application
2.3.4 Market Size By Sample Type
2.3.5 Market Size By End User
2.4 Market Share & BPS Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End Userrs
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Reimbursement & Coverage Trends
4.1.1 Country-wise Payer Coverage Analysis
4.1.2 Cost-Effectiveness and HTA Trends
4.2 R&D Investment and Funding Trends
4.2.1 Venture Capital and IPO Activity (2020–2024)
4.2.2 Public-Private and Regulatory-Backed Initiatives
4.3 Technology Integration Trends
4.3.1 AI and Predictive Analytics
4.3.2 Cloud-Based Genomic Platforms and Registry Integration
4.4 Diagnostic and Treatment Penetration Rates
4.4.1 Newborn Screening Adoption
4.4.2 Treatment Coverage and Penetration
5. Precision Genomic Testing Market Segmental Analysis & Forecast, By Product & Service, 2021 – 2032, Value (USD Billion)
5.1 Introduction
5.2 Consumables
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Instruments
5.3.1 Key Trends
5.3.2 Market Size & Forecast, 2021 – 2032
5.4 Software
5.4.1 Key Trends
5.4.2 Market Size & Forecast, 2021 – 2032
5.5 Services
5.5.1 Key Trends
5.5.2 Market Size & Forecast, 2021 – 2032
5.6 Others (Laboratory automation tools, Storage and logistics solutions specific to genomic workflows)
5.6.1 Key Trends
5.6.2 Market Size & Forecast, 2021 – 2032
6. Precision Genomic Testing Market Segmental Analysis & Forecast, By Technology, 2021 – 2032, Value (USD Billion)
6.1 Introduction
6.2 Next-Generation Sequencing (NGS)
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Polymerase Chain Reaction (PCR)
6.3.1 Key Trends
6.3.2 Market Size & Forecast, 2021 – 2032
6.4 Microarray Technology
6.4.1 Key Trends
6.4.2 Market Size & Forecast, 2021 – 2032
6.5 Sanger Sequencing
6.5.1 Key Trends
6.5.2 Market Size & Forecast, 2021 – 2032
6.6 CRISPR/Cas Systems
6.6.1 Key Trends
6.6.2 Market Size & Forecast, 2021 – 2032
6.7 Others (Whole Genome Amplification (WGA), Nanopore sequencing, Digital PCR (dPCR)
6.7.1 Key Trends
6.7.2 Market Size & Forecast, 2021 – 2032
7. Precision Genomic Testing Market Segmental Analysis & Forecast, By Application, 2021 – 2032, Value (USD Billion)
7.1 Introduction
7.2 Oncology
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Cardiovascular Diseases
7.3.1 Key Trends
7.3.2 Market Size & Forecast, 2021 – 2032
7.4 Neurological Disorders
7.4.1 Key Trends
7.4.2 Market Size & Forecast, 2021 – 2032
7.5 Reproductive & Prenatal Health
7.5.1 Key Trends
7.5.2 Market Size & Forecast, 2021 – 2032
7.6 Infectious Diseases
7.6.1 Key Trends
7.6.2 Market Size & Forecast, 2021 – 2032
7.7 Rare Diseases
7.7.1 Key Trends
7.7.2 Market Size & Forecast, 2021 – 2032
7.8 Others (Autoimmune diseases, Metabolic disorders, Personalized wellness, ETC.)
7.8.1 Key Trends
7.8.2 Market Size & Forecast, 2021 – 2032
8. Precision Genomic Testing Market Segmental Analysis & Forecast, By Sample Type, 2021 – 2032, Value (USD Billion)
8.1 Introduction
8.2 Blood Samples
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Tissue Samples
8.3.1 Key Trends
8.3.2 Market Size & Forecast, 2021 – 2032
8.4 Saliva Samples
8.4.1 Key Trends
8.4.2 Market Size & Forecast, 2021 – 2032
8.5 Urine Samples
8.5.1 Key Trends
8.5.2 Market Size & Forecast, 2021 – 2032
8.6 Others (Buccal swabs, Amniotic fluid, ETC.)
8.6.1 Key Trends
8.6.2 Market Size & Forecast, 2021 – 2032
9. Precision Genomic Testing Market Segmental Analysis & Forecast, By End User, 2021 – 2032, Value (USD Billion)
9.1 Introduction
9.2 Hospitals and Clinics
9.2.1 Key Trends
9.2.2 Market Size & Forecast, 2021 – 2032
9.3 Diagnostic Laboratories
9.3.1 Key Trends
9.3.2 Market Size & Forecast, 2021 – 2032
9.4 Research & Academic Institutes
9.4.1 Key Trends
9.4.2 Market Size & Forecast, 2021 – 2032
9.5 Pharmaceutical & Biotechnology Companies
9.5.1 Key Trends
9.5.2 Market Size & Forecast, 2021 – 2032
9.6 Others (Contract research organizations (CROs), Direct-to-consumer (DTC) genetic testing companies)
9.6.1 Key Trends
9.6.2 Market Size & Forecast, 2021 – 2032
10. Precision Genomic Testing Market Segmental Analysis & Forecast By Region, 2021 – 2032, Value (USD Billion)
10.1 Introduction
10.2 North America
10.2.1 Key Trends
10.2.2 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.2.3 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.2.4 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.2.5 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.2.6 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.2.7 Precision Genomic Testing Market Size & Forecast, By Country, 2021 – 2032
10.2.7.1 USA
10.2.7.1.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.2.7.1.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.2.7.1.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.2.7.1.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.2.7.1.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.2.7.2 Canada
10.2.7.2.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.2.7.2.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.2.7.2.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.2.7.2.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.2.7.2.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.3 Europe
10.3.1 Key Trends
10.3.2 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.3.3 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.3.4 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.3.5 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.3.6 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.3.7 Precision Genomic Testing Market Size & Forecast, By Country, 2021 – 2032
10.3.7.1 Germany
10.3.7.1.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.3.7.1.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.1.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.3.7.1.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.3.7.1.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.3.7.2 UK
10.3.7.2.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.3.7.2.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.2.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.3.7.2.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.3.7.2.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.3.7.3 France
10.3.7.3.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.3.7.3.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.3.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.3.7.3.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.3.7.3.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.3.7.4 Italy
10.3.7.4.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.3.7.4.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.4.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.3.7.4.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.3.7.4.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.3.7.5 Spain
10.3.7.5.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.3.7.5.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.5.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.3.7.5.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.3.7.5.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.3.7.6 Russia
10.3.7.6.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.3.7.6.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.6.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.3.7.6.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.3.7.6.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.3.7.7 Poland
10.3.7.7.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.3.7.7.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.7.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.3.7.7.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.3.7.7.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.3.7.8 Rest of Europe
10.3.7.8.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.3.7.8.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.8.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.3.7.8.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.3.7.8.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.4 Asia-Pacific
10.4.1 Key Trends
10.4.2 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.4.3 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.4.4 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.4.5 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.4.6 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.4.7 Precision Genomic Testing Market Size & Forecast, By Country, 2021 – 2032
10.4.7.1 China
10.4.7.1.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.4.7.1.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.1.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.4.7.1.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.4.7.1.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.4.7.2 India
10.4.7.2.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.4.7.2.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.2.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.4.7.2.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.4.7.2.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.4.7.3 Japan
10.4.7.3.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.4.7.3.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.3.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.4.7.3.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.4.7.3.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.4.7.4 South Korea
10.4.7.4.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.4.7.4.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.4.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.4.7.4.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.4.7.4.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.4.7.5 Australia
10.4.7.5.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.4.7.5.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.5.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.4.7.5.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.4.7.5.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.4.7.6 ASEAN Countries
10.4.7.6.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.4.7.6.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.6.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.4.7.6.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.4.7.6.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.4.7.7 Rest of Asia-Pacific
10.4.7.7.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.4.7.7.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.7.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.4.7.7.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.4.7.7.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.5 Latin America
10.5.1 Key Trends
10.5.2 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.5.3 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.5.4 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.5.5 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.5.6 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.5.7 Precision Genomic Testing Market Size & Forecast, By Country, 2021 – 2032
10.5.7.1 Brazil
10.5.7.1.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.5.7.1.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.5.7.1.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.5.7.1.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.5.7.1.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.5.7.2 Argentina
10.5.7.2.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.5.7.2.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.5.7.2.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.5.7.2.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.5.7.2.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.5.7.3 Mexico
10.5.7.3.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.5.7.3.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.5.7.3.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.5.7.3.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.5.7.3.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.5.7.4 Colombia
10.5.7.4.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.5.7.4.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.5.7.4.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.5.7.4.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.5.7.4.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.5.7.5 Rest of Latin America
10.5.7.5.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.5.7.5.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.5.7.5.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.5.7.5.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.5.7.5.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.6 Middle East & Africa
10.6.1 Key Trends
10.6.2 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.6.3 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.6.4 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.6.5 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.6.6 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.6.7 Precision Genomic Testing Market Size & Forecast, By Country, 2021 – 2032
10.6.7.1 UAE
10.6.7.1.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.6.7.1.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.6.7.1.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.6.7.1.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.6.7.1.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.6.7.2 Saudi Arabia
10.6.7.2.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.6.7.2.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.6.7.2.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.6.7.2.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.6.7.2.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.6.7.3 Qatar
10.6.7.3.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.6.7.3.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.6.7.3.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.6.7.3.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.6.7.3.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.6.7.4 Egypt
10.6.7.4.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.6.7.4.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.6.7.4.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.6.7.4.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.6.7.4.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.6.7.5 South Africa
10.6.7.5.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.6.7.5.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.6.7.5.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.6.7.5.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.6.7.5.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
10.6.7.6 Rest of Middle East & Africa
10.6.7.6.1 Precision Genomic Testing Market Size & Forecast, By Product & Service, 2021 – 2032
10.6.7.6.2 Precision Genomic Testing Market Size & Forecast, By Technology, 2021 – 2032
10.6.7.6.3 Precision Genomic Testing Market Size & Forecast, By Application, 2021 – 2032
10.6.7.6.4 Precision Genomic Testing Market Size & Forecast, By Sample Type, 2021 – 2032
10.6.7.6.5 Precision Genomic Testing Market Size & Forecast, By End User, 2021 – 2032
11. Competitive Landscape
11.1 Key Players' Positioning
11.2 Competitive Developments
11.2.1 Key Strategies Adopted (%), By Key Players, 2024
11.2.2 Year-Wise Strategies & Development, 2021 – 2025
11.2.3 Number Of Strategies Adopted By Key Players, 2024
11.3 Market Share Analysis, 2024
11.4 Product/Service & Application Benchmarking
11.4.1 Product/Service Specifications & Features By Key Players
11.4.2 Product/Service Heatmap By Key Players
11.4.3 Application Heatmap By Key Players
11.5 Industry Start-Up & Innovation Landscape
11.6 Key Company Profiles
11.6 Key Company Profiles
11.6.1 Thermo Fisher Scientific
11.6.1.1 Company Overview & Snapshot
11.6.1.2 Product/Service Portfolio
11.6.1.3 Key Company Financials
11.6.1.4 SWOT Analysis
11.6.2 Illumina
11.6.2.1 Company Overview & Snapshot
11.6.2.2 Product/Service Portfolio
11.6.2.3 Key Company Financials
11.6.2.4 SWOT Analysis
11.6.3 Roche
11.6.3.1 Company Overview & Snapshot
11.6.3.2 Product/Service Portfolio
11.6.3.3 Key Company Financials
11.6.3.4 SWOT Analysis
11.6.4 QIAGEN
11.6.4.1 Company Overview & Snapshot
11.6.4.2 Product/Service Portfolio
11.6.4.3 Key Company Financials
11.6.4.4 SWOT Analysis
11.6.5 Agilent Technologies
11.6.5.1 Company Overview & Snapshot
11.6.5.2 Product/Service Portfolio
11.6.5.3 Key Company Financials
11.6.5.4 SWOT Analysis
11.6.6 Guardant Health
11.6.6.1 Company Overview & Snapshot
11.6.6.2 Product/Service Portfolio
11.6.6.3 Key Company Financials
11.6.6.4 SWOT Analysis
11.6.7 Foundation Medicine
11.6.7.1 Company Overview & Snapshot
11.6.7.2 Product/Service Portfolio
11.6.7.3 Key Company Financials
11.6.7.4 SWOT Analysis
11.6.8 Exact Sciences
11.6.8.1 Company Overview & Snapshot
11.6.8.2 Product/Service Portfolio
11.6.8.3 Key Company Financials
11.6.8.4 SWOT Analysis
11.6.9 Myriad Genetics
11.6.9.1 Company Overview & Snapshot
11.6.9.2 Product/Service Portfolio
11.6.9.3 Key Company Financials
11.6.9.4 SWOT Analysis
11.6.10 GRAIL
11.6.10.1 Company Overview & Snapshot
11.6.10.2 Product/Service Portfolio
11.6.10.3 Key Company Financials
11.6.10.4 SWOT Analysis
11.6.11 Oxford Nanopore Technologies
11.6.11.1 Company Overview & Snapshot
11.6.11.2 Product/Service Portfolio
11.6.11.3 Key Company Financials
11.6.11.4 SWOT Analysis
11.6.12 PacBio
11.6.12.1 Company Overview & Snapshot
11.6.12.2 Product/Service Portfolio
11.6.12.3 Key Company Financials
11.6.12.4 SWOT Analysis
11.6.13 10x Genomics
11.6.13.1 Company Overview & Snapshot
11.6.13.2 Product/Service Portfolio
11.6.13.3 Key Company Financials
11.6.13.4 SWOT Analysis
11.6.14 Genomic Health
11.6.14.1 Company Overview & Snapshot
11.6.14.2 Product/Service Portfolio
11.6.14.3 Key Company Financials
11.6.14.4 SWOT Analysis
11.6.15 Revvity
11.6.15.1 Company Overview & Snapshot
11.6.15.2 Product/Service Portfolio
11.6.15.3 Key Company Financials
11.6.15.4 SWOT Analysis
11.6.16 GenScript
11.6.16.1 Company Overview & Snapshot
11.6.16.2 Product/Service Portfolio
11.6.16.3 Key Company Financials
11.6.16.4 SWOT Analysis
11.6.17 Maravai LifeSciences
11.6.17.1 Company Overview & Snapshot
11.6.17.2 Product/Service Portfolio
11.6.17.3 Key Company Financials
11.6.17.4 SWOT Analysis
11.6.18 Abbott Laboratories
11.6.18.1 Company Overview & Snapshot
11.6.18.2 Product/Service Portfolio
11.6.18.3 Key Company Financials
11.6.18.4 SWOT Analysis
11.6.19 Danaher Corporation
11.6.19.1 Company Overview & Snapshot
11.6.19.2 Product/Service Portfolio
11.6.19.3 Key Company Financials
11.6.19.4 SWOT Analysis
11.6.20 NantHealth
11.6.20.1 Company Overview & Snapshot
11.6.20.2 Product/Service Portfolio
11.6.20.3 Key Company Financials
11.6.20.4 SWOT Analysis
12. Analyst Recommendations
12.1 SNS Insider Opportunity Map
12.2 Industry Low-Hanging Fruit Assessment
12.3 Market Entry & Growth Strategy
12.4 Analyst Viewpoint & Suggestions On Market Growth
13. Assumptions
14. Disclaimer
15. Appendix
15.1 List Of Tables
15.2 List Of Figures
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segment
By Product & Service
By Technology
By Application
By Sample Type
By End User
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
Europe
Asia Pacific
Middle East & Africa
Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report: